- Home
- RUBI vs GTBP Comparison
RUBI vs GTBP Comparison
Compare RUBI & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUBI | GTBP |
|---|---|---|
| Founded | N/A | 1965 |
| Country | Marshall Islands | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RUBI | GTBP |
|---|---|---|
| Price | $1.65 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 1.6M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,139,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.63 | $0.54 |
| 52 Week High | $200.70 | $4.10 |
Technical Indicators
Market Signals| Indicator | RUBI | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.17 |
| Support Level | N/A | $0.58 |
| Resistance Level | N/A | $0.82 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 32.15 |
Price Performance
Historical ComparisonAbout RUBI Rubico Inc. Common Stock
Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.